| |
Wednesday, March 26, 2025 | 12pm ET / 9am PT Join us for this exclusive webinar to gain actionable insights from industry experts on the top challenges of HCP engagement and latest strategies for driving commercial success. Register today. 
|
|
Today’s Big NewsMar 20, 2025 |
|
Thursday, March 27, 2025 | 11am ET / 8am PT This webinar will explore the growing need for process intensification in bioprocessing as a crucial step toward enhancing efficiency and sustainability. Join us to gain valuable insights into overcoming challenges related to bioprocess scale-up, including the adaptation of novel bioreactors, media formulations, and cell culture practices. Register now. 
|
|
| By James Waldron Novo Nordisk may be reorganizing its early-stage R&D capabilities, but the Danish pharma’s chief scientific officer has insisted that the changes aren’t primarily about laying off staff. |
|
|
|
By Angus Liu Global pharma giants AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, Novartis, Pfizer and more are calling for the U.K. government to afford the industry more room for growth by revising a drug cost control program. |
By Conor Hale A randomized study from Insulet of adults and children with Type 1 diabetes found that moving from multiple daily injections of insulin to their first automated pump improved users’ time in a healthy glucose range and lowered their HbA1c. |
By Gabrielle Masson Despite a historic FDA approval last year, Adaptimmune Therapeutics is expressing concerns about the longevity of the company and has resorted to cutting preclinical programs and evaluating strategic options. |
|
Thursday, April 3, 2025 | 11am ET / 8am PT Join us for an insightful webinar on the latest advancements in cell and gene therapy, focusing on the innovative Cas9-CLIPT (Cleaved, Linearized with Protein Template) technology. Learn more about this groundbreaking technology designed to improve the efficiency of genome editing. Register now.  
|
|
By Angus Liu As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer, the British pharma has rolled out early data from a trial combining the antibody-drug conjugate with its old blockbuster Tagrisso. |
By Darren Incorvaia British investment firm SV Health Investors has secured $250 million to go toward the development of first-in-class therapeutics for dementia, the second such fund the venture capitalists have put together. |
By James Waldron The CD20-directed antibody, dubbed DR-0201, is a bispecific myeloid cell engager that Dren has been testing in a phase 1 trial for B-cell non-Hodgkin lymphoma. |
By James Waldron Elevation is ditching its sole clinical-stage asset in the wake of disappointing phase 1 data, leading the antibody-drug conjugate company to lay off 70% of its staff. |
By Kevin Dunleavy In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic rhinosinusitis (CRS) nasal spray Xhance for up to $330 million. |
By Zoey Becker Two "concerned shareholders" are calling for an immediate strategic review at Amarin two years after a heated public back-and-forth between Amarin and another activist investor, Sarissa Capital. |
By Gabrielle Masson Century Therapeutics has joined the onslaught of cell therapy biotechs taking hits, discontinuing a phase 1 cancer study to turn its focus toward autoimmune diseases. |
By Joseph Keenan Aspen Pharmacare, the largest drugmaker on the African continent, was slammed in a warning letter by the FDA citing sterility issues that could lead to microbial contamination. The write-up follows a September inspection of Aspen's Gqeberha, South Africa, plant, which produces eye drops and other sterile medicines. |
By Andrea Park In an attempt to strike a pitch-perfect tone with Generation X, Pfizer has recruited Elizabeth Banks as the face of a new awareness campaign for pneumococcal pneumonia vaccination. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we dissect the unprecedented revenue growth enjoyed by many major pharma companies in 2024’s fourth quarter. |
|
|---|
|
|
Whitepaper Read about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
Whitepaper Develop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| |
|
